Monday, May 24, 2010

Neurocrine Biosciences Finds "statistically significant and clinically meaningful" results in the battle against Endometriosis

The stock doubled after hours and since this disease might afflict up to 5 - 10% of all women this is a pretty good deal.

“The Daisy PETAL study was successful, all primary and secondary efficacy endpoints were met, and provided exactly the information we need to move this program forward,” said Chris O’Brien, M.D., Chief Medical Officer at Neurocrine. “We now have confirmation that the daily scales for menstrual and non-menstrual pelvic pain, developed with extensive input from the FDA and patients, function well in a clinical trial setting. These daily endpoints reflect the way women with endometriosis experience their symptoms and also demonstrate improvement with elagolix.”

The drug is used mostly to reduce pelvic pain from this disease and is a Gonadotropin-Releasing Hormone (GnRH) receptor antagonist. I guess that means it is a specialized hormone pill since Gonadotropin is used as a fertility drug for men. What is interesting is that Manny Ramirez was suspended last year for 50 games for taking this hormone.

The drug seems pretty safe as well with only 4.4% of people dropping out of the study with the biggest side affect being nausea. Sounds like it could be a pretty good drug if it gets to market.

No comments: